By country
How many people are vaccinated, and how much disease is reported, where you live: WHO/UNICEF coverage estimates beside each country's own figure, reported cases, and the national schedule, with a data-quality grade on every series.
Vaccination rates and disease by country → Compare countries by disease How grades work
BCG vaccine
Tuberculosis (all forms), Tuberculous meningitis and miliary tuberculosis in children
29 risk · 10 post-acute · 32 efficacy · 2 safety
COVID-19 vaccines
COVID-19 (acute), Post-acute sequelae of SARS-CoV-2 infection (long COVID, MIS-C, post-infection cardiovascular events)
13 risk · 11 post-acute · 37 efficacy · 2 safety
DTaP / Tdap (diphtheria, tetanus, pertussis)
Pertussis (whooping cough), Diphtheria, Tetanus
49 risk · 2 post-acute · 76 efficacy · 2 safety
Hepatitis A vaccine
Hepatitis A
39 risk · 1 post-acute · 39 efficacy · 0 safety
Hepatitis B vaccine
Acute hepatitis B, Chronic hepatitis B infection, Cirrhosis and hepatocellular carcinoma after chronic hepatitis B
33 risk · 11 post-acute · 69 efficacy · 0 safety
Hib (Haemophilus influenzae type b) vaccine
Invasive Haemophilus influenzae type b disease (meningitis, pneumonia, epiglottitis, bacteraemia), Sequelae of Hib meningitis (hearing loss, neurodisability)
36 risk · 11 post-acute · 45 efficacy · 2 safety
HPV vaccines (2v, 4v, 9v)
Genital HPV infection (prevalence, persistent infection), Cervical precancer (CIN2+/CIN3+, AIS), Cervical cancer, Other HPV-attributable cancers (anal, oropharyngeal, vulvar, vaginal, penile) and genital warts / papillomatosis
23 risk · 10 post-acute · 90 efficacy · 5 safety
Influenza (seasonal) vaccines
Seasonal influenza (including the 2009 A(H1N1)pdm09 pandemic), Post-influenza cardiovascular events (myocardial infarction, stroke)
37 risk · 9 post-acute · 105 efficacy · 0 safety
Japanese encephalitis vaccines (Ixiaro, SA 14-14-2, Imojev)
Japanese encephalitis, Neurological, cognitive and psychiatric sequelae after Japanese encephalitis
29 risk · 11 post-acute · 32 efficacy · 2 safety
Meningococcal vaccines (MenACWY, MenB, MenC, MenA conjugate)
Invasive meningococcal disease (meningitis and septicaemia), Sequelae of invasive meningococcal disease (hearing loss, amputation, neurological and psychological deficits)
39 risk · 14 post-acute · 53 efficacy · 0 safety
MMR (measles, mumps, rubella)
Measles, Mumps, Rubella, Chickenpox (varicella)
7 risk · 2 post-acute · 17 efficacy · 5 safety
Oral cholera vaccines (Shanchol, Euvichol, Dukoral, Vaxchora)
Cholera
29 risk · 0 post-acute · 96 efficacy · 0 safety
Pneumococcal conjugate vaccines (PCV7/10/13/15/20) and PPSV23
Invasive pneumococcal disease (bacteraemia, meningitis, bacteraemic pneumonia), Pneumococcal pneumonia (community-acquired, non-invasive), Sequelae after pneumococcal meningitis (hearing loss, neurological disability)
38 risk · 8 post-acute · 74 efficacy · 1 safety
Polio vaccines (IPV, OPV)
Poliomyelitis, Post-polio syndrome
50 risk · 10 post-acute · 59 efficacy · 12 safety
Rabies vaccines (pre- and post-exposure prophylaxis)
Rabies
30 risk · 1 post-acute · 45 efficacy · 3 safety
Rotavirus vaccines (RotaTeq, Rotarix, Rotavac, Rotasiil)
Rotavirus gastroenteritis
30 risk · 0 post-acute · 88 efficacy · 13 safety
RSV vaccines (Arexvy RSVPreF3 OA, Abrysvo RSVpreF, mResvia mRNA-1345), maternal RSVpreF, and nirsevimab (monoclonal antibody)
RSV lower respiratory tract infection in infants and young children, RSV disease in older adults, Recurrent wheeze and asthma after infant RSV infection
35 risk · 8 post-acute · 55 efficacy · 5 safety
Shingles (herpes zoster) vaccines
Herpes zoster (shingles), Post-herpetic neuralgia, Stroke and myocardial infarction after herpes zoster
28 risk · 18 post-acute · 56 efficacy · 3 safety
Typhoid vaccines (TCV Typbar, Vi polysaccharide, Ty21a)
Typhoid fever
44 risk · 4 post-acute · 68 efficacy · 3 safety
Varicella (chickenpox) vaccine
Chickenpox (varicella), Congenital varicella syndrome and neonatal varicella, Herpes zoster after wild-type varicella infection
37 risk · 11 post-acute · 59 efficacy · 2 safety
Yellow fever vaccine (17D)
Yellow fever
26 risk · 0 post-acute · 48 efficacy · 18 safety